劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

交易中 07-23 13:17:34

35.780

-1.000

-2.72%

最高36.820	最低35.000	成交量90.74万
今开36.700	昨收36.780	日振幅4.95%
总市值137.40亿	流通市值125.95亿	总股本3.84亿
成交额3,260万	换手率0.26%	流通股本3.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":35.78,"timestamp":1784783842452,"preClose":36.78,"halted":0,"volume":907392,"delay":0,"changeRate":-0.02718868950516585,"floatShares":352000000,"shares":384000000,"eps":-6.07,"marketStatus":"交易中","change":-1,"latestTime":"07-23 13:17:34","open":36.7,"high":36.82,"low":35,"amount":32599311,"amplitude":0.049483,"askPrice":35.78,"askSize":5800,"bidPrice":35.7,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-5.174,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784794200000},"marketStatusCode":2,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":36.78,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.744715,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"2653744752","title":"Wellington Management Group LLP减持劲方医药-B(02595)8400股 每股作价约34.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744752","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653744752?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:18","pubTimestamp":1784719136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月20日，Wellington Management Group LLP减持劲方医药-B(02595)8400股，每股作价34.7105港元，总金额约为29.16万港元。减持后最新持股数目约为2444.11万股，最新持股比例为6.95%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","BK1574","09939","159938","EWH","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178119709","title":"异动解读｜劲方医药-B盘中上涨5.76%，配售落地后股价技术性修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1178119709","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178119709?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:28","pubTimestamp":1784611682,"startTime":"0","endTime":"0","summary":"7月21日，劲方医药-B盘中上涨5.76%，报38.2港元/股，成交额2611.66万港元。消息面上，公司于7月17日完成1360万股新H股配售，每股配售价34.69港元，净筹约4.67亿港元，用于推进核心产品RAS抑制剂GFH276、GFS202A及GFS784等创新管线研发。配售当日股价下跌8.56%，今日股价在配售价上方展开修复。此外，公司多项研究数据已获WCLC、ESMO口头报告或突破性研究摘要入选，核心管线GFH375此前已获两项突破性疗法认定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101958803","title":"劲方医药-B配发及发行1360万股H股，涉资约4.72亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101958803","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101958803?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:51","pubTimestamp":1784289114,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（劲方医药-B，股票代码：02595）于2026年7月17日发布公告，宣布根据于2026年7月14日订立的配售协议，并依据一般授权，配发及发行13,600,000股新H股。该等股份占发行前已发行股本约4.02%，每股发行价为34.69港元，总发行金额约为4.72亿港元。\n本次股份发行完成后，公司已发行股本由338,029,020股增至351,629,020股，公司库藏股维持不变。公司在公告中确认，相关发行已获得董事会正式授权，并符合香港联合交易所有限公司的上市规则及其他相关法规。\n本公告由联席公司秘书张巍签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B配发及发行1360万股H股，涉资约4.72亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652205288","title":"Wellington Management Group LLP增持劲方医药(02595)139.74万股 每股作价34.69港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652205288","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652205288?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:41","pubTimestamp":1784288466,"startTime":"0","endTime":"0","summary":"7月15日，Wellington Management Group LLP增持劲方医药(02595)139.74万股，每股作价34.69港元，总金额约为4847.58万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260717/20260717194140_39306.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260717/20260717194140_39306.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","02595","09939","EWH","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652840045","title":"劲方医药-B(02595)完成发行1360万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652840045","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652840045?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:38","pubTimestamp":1784288297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，配售协议所载的全部条件已获达成，且交割已根据配售协议的条款于2026年7月17日进行。配售代理已根据配售协议的条款及条件按配售价每股配售股份34.69港元成功向不少于六名承配人配售合共1360万股配售股份，于本公告日期，约占经配发及发行配售股份扩大后的H股的3.87%及已发行股份总数的3.54%。配售的所得款项总额为4.718亿港元，而配售的所得款项净额为约4.669亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159938","BK1515","02595","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174244833","title":"劲方医药-B(02595)完成3.54%新H股配售  净筹4.67亿港元并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1174244833","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174244833?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:35","pubTimestamp":1784288127,"startTime":"0","endTime":"0","summary":"2026年7月17日，劲方医药科技（上海）股份有限公司公告称，公司已完成根据董事会一般授权进行的新H股配售，并同步修订公司章程。本次配售由独家全球协调人负责承销，配售协议的全部条件已于2026年7月17日达成并完成交割。配售价格为每股34.69港元，向不少于六名承配人发行合计13,600,000股H股，占配售完成后扩大后已发行H股的约3.87%，占已发行股份总数的约3.54%。其中，未上市股份保持32,337,610股，占总股本的8.42%；H股增至351,629,020股，占总股本的91.58%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155736708","title":"异动解读｜劲方医药-B盘中下跌8.2%，报35.84港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155736708","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155736708?lang=zh_cn&edition=full","pubTime":"2026-07-17 11:10","pubTimestamp":1784257818,"startTime":"0","endTime":"0","summary":"7月17日，劲方医药-B盘中下跌8.2%，报35.84港元/股，成交额3741.79万港元。劲方医药-B所在的生物科技行业整体承压，个股中，康方生物跌11.64%，三生制药跌11.5%，信达生物跌5.57%，科伦博泰生物跌5.45%，百济神州跌2.62%。值得关注的是，公司于7月15日公告拟折价约9.71%配售1360万股新H股，净筹约4.67亿港元用于推进RAS抑制剂等核心管线研发，此前两个交易日股价累计大幅上涨后，今日随板块整体回落。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651380424","title":"港股异动 | 劲方医药-B(02595.HK)早盘涨超7% 拟配股净筹约4.7亿港元 用于推进核心产品RAS抑制剂等","url":"https://stock-news.laohu8.com/highlight/detail?id=2651380424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651380424?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:46","pubTimestamp":1784079989,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","BK1161","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131195780","title":"港股直击｜医药股及医药外包股造好，昭衍新药升6%，劲方医药、康宁杰瑞制药升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131195780","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131195780?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:38","pubTimestamp":1784079537,"startTime":"0","endTime":"0","summary":"医药股及医药外包股造好，劲方医药升逾 5%，拟折价约9.71%配售1360万股配售股份，净筹约4.67亿港元；康宁杰瑞制药升 5%，康方生物升 4%，昭衍新药升 6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651748241","title":"劲方医药-B(02595)拟折价约9.71%配售1360万股配售股份 净筹约4.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651748241","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651748241?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:26","pubTimestamp":1784071605,"startTime":"0","endTime":"0","summary":"配售项下的配售股份总面值将为人民币136万元。假设全部1360万股配售股份获悉数认购，于交割时，所得款项总额将为4.72亿港元，而配售产生的所得款项净额估计为4.67亿港元。基于此，每股配售股份的净发行价将约为34.33港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","09939","BK1161","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130806586","title":"劲方医药-B(02595)拟配售1,360万股H股 料募资4.72亿港元加码RAS管线研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130806586","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130806586?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:25","pubTimestamp":1784071547,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司7月15日公告，已于2026年7月14日与摩根士丹利亚洲有限公司及中信里昂证券有限公司签署配售协议，拟按每股34.69港元向不少于六名承配人配售1,360万股新H股。本次配售股份数占公告日已发行H股4.02%，占已发行股份总数3.67%；配售完成后，分别占扩大后已发行H股3.87%、已发行股份总数3.54%。配售股份面值合计人民币136万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104303513","title":"劲方医药-B配售所得款项总额达47.18亿港元 净额预计约46.69亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104303513","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104303513?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:22","pubTimestamp":1784071334,"startTime":"0","endTime":"0","summary":"劲方医药-B宣布，其配售计划已获得总额约47.18亿港元的毛收入。经扣除相关开支后，公司预计此次配售的净收益约为46.69亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186295881","title":"一周港股牛熊榜 | 德适生物飙逾47%登顶牛股榜；深演智能升逾40%，机构料其有望9月入通；建滔系两只股周挫逾25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186295881","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186295881?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:57","pubTimestamp":1783677445,"startTime":"0","endTime":"0","summary":"值得一提的是，恒生指数公司或于8月25日公布半年度指数调整结果，9月7日港股通名单将调整。华泰证券预计深演智能有望入通。其H股已于2026年6月26日在香港联交所主板正式挂牌上市，股份代号为01688。此次上市的H股数目为8.12亿股。公司的A股则继续于深圳证券交易所上市，股份代号为002600。其中沽空股數按日大增24700%，至9,920股；沽空佔比則增加9024%，至3.52%，兩項數據均高於月度平均水平，反映市場沽空壓力升溫。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","01888","02526","09988","01688","02595","00148","09903","02723","02718"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650946328","title":"港股异动 | 劲方医药-B(02595.HK)涨超6% GFH375具备同类最佳潜力 正开展针对二线及以上胰腺癌III期注册性临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2650946328","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650946328?lang=zh_cn&edition=full","pubTime":"2026-07-09 13:47","pubTimestamp":1783576030,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","BK1161","02595","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998075","title":"Wellington Management Group LLP减持劲方医药-B(02595)约35.16万股 每股作价约33.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998075","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649998075?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:32","pubTimestamp":1783510377,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月6日，Wellington Management Group LLP减持劲方医药-B(02595)35.1645万股，每股作价33.643港元，总金额约为1183.04万港元。减持后最新持股数目约为2336.97万股，持股比例为6.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","EWH","02595","BK1515","159938","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164680693","title":"劲方医药-B发布2026年6月股份变动月报，股本持平无新增发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1164680693","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164680693?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:32","pubTimestamp":1783333953,"startTime":"0","endTime":"0","summary":"劲方医药-B于2026年7月6日更新2026年6月股份变动月报。报告期覆盖截至2026年6月30日的股份情况。根据公告，普通股H股维持338,029,020股，未上市普通股维持32,337,610股，两者合计370,366,630股，面值均为人民币0.1元，注册股本总额约为人民币37,036,663元。上述数量较上月无变化，未发生新增发行、购回、注销或库藏股变动。本次月报由公司联席公司秘书张巍签署。公告强调，公司持续遵守香港联交所《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648572826","title":"【券商聚焦】申万宏源首予劲方医药-B(02595)“买入”评级 指其RAS疗法具全球领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2648572826","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648572826?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:51","pubTimestamp":1782975101,"startTime":"0","endTime":"0","summary":"报告首次覆盖给予“买入”评级，目标价34.81港元。研报核心逻辑围绕公司核心管线GFH375的全球领先地位展开。GFH375是一款靶向KRAS G12D高频突变的口服抑制剂，该突变在胰腺癌中突变率约40%，且与不良预后密切相关。公司核心产品GFH375预计于2028年上市并开始贡献产品销售收入。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984986","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","159938","000166","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647323800","title":"劲方医药-B午后涨超15% 交银国际维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647323800","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647323800?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:22","pubTimestamp":1782710520,"startTime":"0","endTime":"0","summary":"　　劲方医药-B午后股价上涨15.06%，现报27.96港元，成交额4010.55万港元。　　据劲方医药官微消息，公司宣布GFH375/VS-7375进入一项II期海外研究，治疗KRAS G12D突变型转移性胰腺导管腺癌，并已于近日完成首例患者入组。　　交银国际发布研报称，将劲方医药的投资评级及目标价，分别维持“买入”评级及目标价51港元。该行称，KRAS G12D 抑制剂海外临床及合作进展理想。交银国际认为,优异的海外初步数据对 VS7375 的同类最佳潜性提供进一步佐证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-29/doc-inifacku5422211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647285693","title":"劲方医药-B(02595.HK)：拟不超3.5亿港元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2647285693","media":"中金财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647285693?lang=zh_cn&edition=full","pubTime":"2026-06-29 12:27","pubTimestamp":1782707222,"startTime":"0","endTime":"0","summary":"格隆汇6月29日丨劲方医药-B(02595.HK)公布，2026年6月29日，董事会正式决议行使购回股份授权，拟不定时于公开市场购回H股，最高金额不超过3.5亿港元，股份购回期限至购回股份授权期限届满。公司会在符合香港联合交易所有限公司证券上市规则的情况下进行股份购回。\r\n\r\n　　董事会认为，目前股份的交易价格低估了公司的内在价值及发展前景，而进行股份购回将提升股东价值。股份购回表明董事会对公司长期发展的信心，且仅会在董事会经持续评估公司业务前景、财务状况、股价表现及市场环境，认为适当且符合公司及股东整体利益的情况下进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260629/32292864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","09939","BK1161","BK1574","02595","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340711","title":"劲方医药-B(02595.HK)拟不超过3.5亿港元回购H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340711?lang=zh_cn&edition=full","pubTime":"2026-06-29 12:12","pubTimestamp":1782706342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02595","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":-0.1325},{"period":"1month","weight":0.323},{"period":"3month","weight":-0.1874},{"period":"6month","weight":0.2683},{"period":"1year","weight":0.8038},{"period":"ytd","weight":0.5467}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}